Walmart Stake Sale by Walton Family Trust Generates $329 Million

Jefferson Capital opened at $19 on its first trading day, following a pricing of $15. The IPO market experienced a slow first week of summer, with Circle seeing coverage roll out and Omada Health set to receive new coverage as banks' quiet periods expire. Upcoming IPOs include McGraw Hill, Center Mobile, Fitness Champs, Happy City, and Odyssey Therapeutics.

Jefferson Capital's IPO marked a significant event in the distressed debt sector, opening at $19 on its first trading day, following a pricing of $15. The offering, dominated by secondary sales, has sparked interest among contrarian investors who see potential in the company's global expansion and robust financial performance.

The IPO's structure is notable for its heavy reliance on secondary sales, with 93% of the 10 million shares being sold by existing investors. This liquidity event for insiders, including majority shareholder J.C. Flowers & Co., which will reduce its stake from 81.7% to ~67.5% post-offering, signals a focus on insider liquidity rather than primary shareholder gains [1].

The valuation at the midpoint of the $15–$17 price range suggests a $1.03 billion valuation, compared to adjusted net income of $153.6 million in 2024, implying a price-to-earnings (P/E) ratio of ~6.7x. While elevated debt and cyclical revenue streams temper this, the metric suggests potential upside if the company's growth trajectory holds.

Jefferson's core business—purchasing and resolving non-performing loans (NPLs)—thrives in economic uncertainty. With global NPL volumes projected to rise as interest rates linger at elevated levels, the company's footprint in the U.S., U.K., Canada, and emerging markets like Mexico and Chile positions it to capitalize. Its recent expansion into performing loan purchases adds diversification, reducing reliance on distressed debt alone [1].

However, the IPO is not without risks. The company carries $524 million in floating-rate debt, with interest costs already consuming ~7% of its 2024 revenue. Rising rates or a slowdown in NPL sales could squeeze margins. Additionally, operating in 12+ jurisdictions exposes the firm to varying consumer protection laws, with a misstep in compliance potentially disrupting growth. As a controlled company under Nasdaq rules, J.C. Flowers' 67.5% stake post-IPO means minority shareholders have limited say in decisions, which could deter institutional investors and limit liquidity [1].

Investors must weigh whether the influx of new shares from secondary sales will dilute long-term value or signal confidence from existing shareholders. The stock's success hinges on debt management, regulatory resilience, and the impact of secondary sales on momentum.

The IPO market experienced a slow first week of summer, with Circle seeing coverage roll out and Omada Health set to receive new coverage as banks' quiet periods expire. Upcoming IPOs include McGraw Hill, Center Mobile, Fitness Champs, Happy City, and Odyssey Therapeutics.

References:
[1] https://www.ainvest.com/news/jefferson-capital-ipo-contrarian-play-distressed-debt-2506/